Menu Search
Equities

Chemometec A/S

CHEMM:CPH

Chemometec A/S

Actions
Health CareMedical Equipment and Services
  • Price (DKK)472.40
  • Today's Change20.20 / 4.47%
  • Shares traded33.52k
  • 1 Year change+30.35%
  • Beta1.3213
Data delayed at least 15 minutes, as of Nov 22 2024 16:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy2
Outperform0
Hold1
Sell0
Strong Sell0

Share price forecast in DKK

The 2 analysts offering 12 month price targets for ChemoMetec A/S have a median target of 545.00, with a high estimate of 550.00 and a low estimate of 540.00. The median estimate represents a 15.37% increase from the last price of 472.40.
High16.4%550.00
Med15.4%545.00
Low14.3%540.00

Dividends

In 2024, Chemometec A/S reported a dividend of 4.00 DKK, which represents a 33.33% decrease from last year. The 2 analysts covering the company expect dividends of 3.00 DKK for the upcoming fiscal year, a decrease of 25.00%.
Div growth (TTM)-33.33%
More ▼

Earnings history & estimates in DKK

ChemoMetec A/S reported annual 2024 earnings of 7.83 per share on Sep 11, 2024.
Average growth rate-5.82%
More ▼

Revenue history & estimates in DKK

of 109.30m. This bettered the 104.00m estimate of the one analyst covering the company.
Average growth rate+0.92%
ChemoMetec A/S had revenues for the full year 2024 of 407.35m. This was 7.90% below the prior year's results.
Average growth rate-2.18%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.